GlaxoSmithKline US

Molecular Piracy Turns Protein Into Traitor

Researchers have discovered a naturally occurring chemokine antagonist, vMIP-II, which can block both CCR5 and CXCR4 receptors used by HIV to infect human cells. This breakthrough may lead to novel approaches for HIV therapy, including prevention of initial infection and slowing disease progression.

SourceGlaxoSmithKline US·JournalScience·DateSep 5, 1997

Green Light For Chemokine Receptors

A potent chemokine, AOP-RANTES, has been shown to inhibit HIV-1 entry into macrophages and lymphocytes at the nanomolar level. Researchers believe this could lead to a new treatment approach for HIV/AIDS by targeting host cells to prevent viral entry.

SourceGlaxoSmithKline US·DateApr 9, 1997